Linatin Met

Metformin Hydrochloride and Linagliptin, the active ingredients in Linatin Met, are antidiabetic agents presented as a fixed‑dose oral tablet for oral use. The combination lowers blood glucose by reducing hepatic glucose production, enhancing insulin sensitivity, and increasing incretin‑mediated insulin secretion in adults with type 2 diabetes mellitus.

GNH USA supplies Linatin Met as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets with full documentation and quality assurance and timely delivery.

Linatin Met, a fixed‑dose combination antidiabetic medication, is indicated for management of type 2 diabetes mellitus. - Type 2 diabetes mellitus: improves overall glycemic control and reduces HbA1c levels. - Hyperglycemia: lowers fasting plasma glucose and post‑prandial glucose excursions. - Inadequate response to metformin monotherapy: provides additional glucose‑lowering effect when metformin alone is insufficient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: increased bowel movements. - Abdominal discomfort: cramping or pain. - Headache: transient head pain. - Dizziness: light‑headed sensation. - Upper respiratory tract infection: mild cold‑like symptoms.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Severe hypoglycemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: inflammation of the pancreas. - Hepatic dysfunction: elevated liver enzymes. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Renal impairment: worsening kidney function.

Before initiating Linatin Met, consider the following precautions: - Renal function assessment: evaluate eGFR and monitor periodically. - Lactic acidosis risk: avoid in patients with severe renal or hepatic impairment. - Hypoglycemia monitoring: watch for low blood sugar when used with insulin or sulfonylureas. - Pregnancy and lactation: use only if potential benefit justifies the risk. - Drug interactions: review concomitant medications for possible DPP‑4 inhibitor interactions. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Linatin Met may interact with several medicines. Review the following: Major Interactions (Avoid): - Concomitant insulin or sulfonylureas: may cause severe hypoglycemia. - Cimetidine: can increase linagliptin plasma concentrations. - Iodinated contrast agents in patients with renal impairment: risk of acute kidney injury. Moderate Interactions (Monitor Closely): - Metformin with diuretics: may affect renal clearance of metformin. - Alcohol consumption: raises risk of lactic acidosis. - Rifampicin: may reduce linagliptin exposure, diminishing efficacy.